YS
Yatin Suneja
Compare →Managing Director, Biotechnology Analyst at Guggenheim Securities
Yatin Suneja is a Managing Director and Biotechnology Analyst at Guggenheim Securities, specializing in healthcare equity research with a focus on biotechnology companies. He has over 17 years of experience in the field, having previously held senior positions at SunTrust Robinson Humphrey and Cowen and Company.
No chart yet. A chart needs 8 resolved predictions, and Yatin has 6. The predictions themselves are below.
SORT
STILL OPEN
?
Sign in to read this call.
Due Jul 17, 2027July 17, 2026Price targetEquitiesPending
—
SCORE
?
Sign in to read this call.
Due Jul 20, 2027July 20, 2026Price targetEquitiesPending
—
SCORE
?
Biogen will reach a price of $280 within 12 months of Jul 21, 2026.
Due Jul 21, 2027July 21, 2026Price targetEquitiesPending
—
SCORE
?
Neurocrine Biosciences will reach a price of $200 within 12 months of Jul 21, 2026.
Due Jul 21, 2027July 21, 2026Price targetEquitiesPending
—
SCORE
?
Regeneron Pharmaceuticals will reach a price of $1000 within 12 months of Jul 21, 2026.
Due Jul 21, 2027July 21, 2026Price targetEquitiesPending
—
SCORE
?
argenx SE will reach a price of $1135 within 12 months of Jul 21, 2026.
Due Jul 21, 2027July 21, 2026Price targetEquitiesPending
—
SCORE
?
Phathom Pharmaceuticals will reach a price of $25 within 12 months of Jul 21, 2026.
Due Jul 21, 2027July 21, 2026Price targetEquitiesPending
—
SCORE
?
Spyre Therapeutics will reach a price of $115 within 12 months of Jul 24, 2026.
Due Jul 24, 2027July 24, 2026Price targetEquitiesPending
—
SCORE
?
Sionna Therapeutics will reach a price of $50 within 12 months of Jul 24, 2026.
Due Jul 24, 2027July 24, 2026Price targetEquitiesPending
—
SCORE
?
Yatin Suneja predicts a price target of $20.00 for Zura Bio within 12 months after boosting the price target.
Due Aug 12, 2027August 12, 2026BiotechnologyPending
—
SCORE
?
Yatin Suneja predicts a price target of $55.00 for Zenas BioPharma within 12 months after reiterating the rating.
Due Aug 14, 2027August 14, 2026BiotechnologyPending
—
SCORE
?
Yatin Suneja predicts a price target of $50.00 for Latigo Biotherapeutics within 12 months after initiating coverage.
Due Sep 1, 2027September 1, 2026BiotechnologyPending
—
SCORE
?
Sign in to read this call.
July 9, 2026Price targetEquitiesPending
—
SCORE
?
Sign in to read this call.
March 20, 2026price targetdowngradePending
—
SCORE
RESOLVED · NEWEST FIRST
◇
Sign in to read this call.
March 15, 2023FinanceStockNot settleable
—
SCORE
◇
Sign in to read this call.
March 15, 2023PharmaceuticalsInvestmentNot settleable
—
SCORE
✗
Sign in to read this call.
March 6, 2023call #6FinanceBiotechnologyWrong
7
SCORE
✓
Sign in to read this call.
January 3, 2023call #5PharmaceuticalsCorrect
82
SCORE
◇
Sign in to read this call.
September 28, 2022pharmaceuticalsAlzheimer'sNo verdict
—
SCORE
◇
Sign in to read this call.
September 28, 2022pharmaceuticalsAlzheimer'sNo verdict
—
SCORE
◇
Sign in to read this call.
September 28, 2022pharmaceuticalsAlzheimer'sNo verdict
—
SCORE
◇
Sign in to read this call.
September 28, 2022pharmaceuticalsAlzheimer'sNo verdict
—
SCORE
✓
Sign in to read this call.
August 12, 2022call #4PharmaceuticalsStock PriceCorrect
85
SCORE
✓
Sign in to read this call.
May 27, 2020call #3stocksinvestmentCorrect
85
SCORE
✗
Sign in to read this call.
December 16, 2019call #2stocksinvestmentWrong
0
SCORE
◑
Sign in to read this call.
October 23, 2019call #1Alzheimer'sBiotechPartial
47
SCORE
◇
Sign in to read this call.
December 10, 2017pharmaceuticalmarket potentialNo verdict
—
SCORE
Still open · 14
THE FRONT EDGENot resolved, so they don’t move the score.
?No market prices this claim
Sign in to read this call.
Due Jul 17, 2027Said July 17, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Due Jul 20, 2027Said July 20, 2026Price targetEquities
?No market prices this claim
Biogen will reach a price of $280 within 12 months of Jul 21, 2026.
Due Jul 21, 2027Said July 21, 2026Price targetEquities
?No market prices this claim
Neurocrine Biosciences will reach a price of $200 within 12 months of Jul 21, 2026.
Due Jul 21, 2027Said July 21, 2026Price targetEquities
?No market prices this claim
Regeneron Pharmaceuticals will reach a price of $1000 within 12 months of Jul 21, 2026.
Due Jul 21, 2027Said July 21, 2026Price targetEquities
?No market prices this claim
argenx SE will reach a price of $1135 within 12 months of Jul 21, 2026.
Due Jul 21, 2027Said July 21, 2026Price targetEquities
?No market prices this claim
Phathom Pharmaceuticals will reach a price of $25 within 12 months of Jul 21, 2026.
Due Jul 21, 2027Said July 21, 2026Price targetEquities
?No market prices this claim
Spyre Therapeutics will reach a price of $115 within 12 months of Jul 24, 2026.
Due Jul 24, 2027Said July 24, 2026Price targetEquities
?No market prices this claim
Sionna Therapeutics will reach a price of $50 within 12 months of Jul 24, 2026.
Due Jul 24, 2027Said July 24, 2026Price targetEquities
?No market prices this claim
Yatin Suneja predicts a price target of $20.00 for Zura Bio within 12 months after boosting the price target.
Due Aug 12, 2027Said August 12, 2026Biotechnology
?No market prices this claim
Yatin Suneja predicts a price target of $55.00 for Zenas BioPharma within 12 months after reiterating the rating.
Due Aug 14, 2027Said August 14, 2026Biotechnology
?No market prices this claim
Yatin Suneja predicts a price target of $50.00 for Latigo Biotherapeutics within 12 months after initiating coverage.
Due Sep 1, 2027Said September 1, 2026Biotechnology
?No market prices this claim
Sign in to read this call.
Said July 9, 2026Price targetEquities
?No market prices this claim
Sign in to read this call.
Said March 20, 2026price targetdowngrade